Wedbush analyst Laura Chico raised the firm’s price target on BioCryst (BCRX) to $22 from $21 and keeps an Outperform rating on the shares. While the company preannounced Q4 results and FY26 guidance, additional color was provided following the completion of the Astria Therapeutics acquisition. Management reiterated forward guidance for FY26 as well as peak revenue targets. With the commercial business operating smoothly and additional BCX17725 data tracking to year-end 2026, Wedbush continues to like the setup on BioCryst shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCRX:
- Brand Risks Emerge in BioCryst’s ORLADEYO Sale to Neopharmed as Fragmented Positioning Threatens Long‑Term Value
- BioCryst Earnings Call Highlights Profits, Pipeline Momentum
- BioCryst Boosts HAE Franchise With Astria Acquisition, Guidance
- BioCryst reports Q4 EPS $1.12 vs (13c) last year
- BioCryst sees FY26 revenue $635M-$660M, consensus $657.1M